Diphenhydramine

Generic Name: Diphenhydramine

Brand Names: Acetadryl, Advil PM, Aleve PM, Allegra Cooling Relief Anti-itch, Banophen, Benadryl, Benadryl Itch Stopping, Benadryl-D Allergy and Sinus, Calagel, Damylin With Codeine, Dimetapp Nighttime Cold & Congestion, Diphen, Diphenhist, Diphenist, Excedrin PM Triple Action, Goody's PM, Legatrin PM, Motrin PM, Nytol, Nytol Quickgels, Percogesic Reformulated Jan 2011, Siladryl, Simply Sleep, Sleepinal, Sominex, Triaminic Night Time Cold & Cough, Tylenol PM, Unisom, Unisom Sleep, Vanamine, Wal-dryl, Wal-som (doxylamine), Zzzquil

Drug Type: Small Molecule

Chemical Formula: C_₁₇H_₂₁NO

CAS Number: 58-73-1

Unique Ingredient Identifier: 8GTS82S83M

Background: Diphenhydramine - perhaps known most commonly as its brand name formulation Benadryl - is a first-generation H1 receptor antihistamine that is used extensively for the treatment of seasonal allergies, insect bites and stings, and rashes . However, it also has antiemetic, antitussive, hypnotic, and antiparkinson properties . As histamine receptors exist both ...

Indication: Diphenhydramine is a first-generation histamine H1 receptor antagonist (H1 antihistamine) that is widely available as a non-prescription, over-the-counter (OTC) medication. As an OTC medication, diphenhydramine is typically formulated as tablets and creams indicated for use in treating sneezing, runny nose, itchy/watery eyes, itching of nose or throat, insom...

Associated Conditions: Allergic Reaction, Allergic Rhinitis (AR), Allergic cough, Allergy to Tree Pollen, Anaphylaxis, Angioedema, Common Cold, Conjunctival irritation, Cough, Cough Variant Asthma, Cough caused by Common Cold, Eye allergy, Fever, Insect Bites, Insect Stings, Insomnia, Irritative cough, Itching of the nose, Itching of the throat, Motion Sickness, Nasal Congestion, Oral Mucositis, Pain, Parkinsonian Syndromes, Productive cough, Pruritus, Rash, Rhinorrhoea, Sinus Congestion, Sinus headache, Skin Irritation, Sneezing, Sunburn, Symptoms of Acute Bronchitis Accompanied by Coughing, Upper respiratory tract hypersensitivity reaction, site unspecified, Urticaria, Cold or flu syndrome, Dermatographism, Dry cough, Watery itchy eyes

Associated Therapies: Airway secretion clearance therapy, Expectorant

Clinical Trials

Elotuzumab in Immunoglobulin G4-Related Disease (IgG4-RD)

Phase 2

Terminated

Conditions: IgG4 Related Disease
IgG4-RD

Interventions: Drug: placebo for elotuzumab
Drug: elotuzumab
Drug: methylprednisolone
Drug: diphenhydramine
Drug: acetaminophen
Drug: famotidine
Drug: prednisone

First Posted Date: 2021-06-08

Last Posted Date: 2024-01-11

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 8

Registration Number: NCT04918147

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Mayo Clinic: Pulmonary and Critical Care Medicine, Rochester, Minnesota, United States
🇺🇸
Emory Healthcare, Atlanta, Georgia, United States

Safely Stopping Pre-medications in Patients With Breast Cancer Who Are Receiving Paclitaxel

Phase 2

Completed

Conditions: Anatomic Stage I Breast Cancer AJCC v8
Prognostic Stage IIIA Breast Cancer AJCC v8
Prognostic Stage IV Breast Cancer AJCC v8
Anatomic Stage 0 Breast Cancer AJCC v8
Anatomic Stage IA Breast Cancer AJCC v8
Anatomic Stage IB Breast Cancer AJCC v8
Anatomic Stage II Breast Cancer AJCC v8
Anatomic Stage IIA Breast Cancer AJCC v8
Anatomic Stage IIB Breast Cancer AJCC v8
Anatomic Stage III Breast Cancer AJCC v8

Interventions: Drug: Cimetidine
Drug: Dexamethasone
Drug: Diphenhydramine
Drug: Famotidine
Drug: Paclitaxel
Other: Quality-of-Life Assessment
Drug: Ranitidine

First Posted Date: 2021-04-28

Last Posted Date: 2024-08-09

Lead Sponsor: Ohio State University Comprehensive Cancer Center

Target Recruit Count: 129

Registration Number: NCT04862585

Locations: 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States

TReatment for ImmUne Mediated PathopHysiology

Phase 2

Recruiting

Conditions: Fulminant Hepatic Failure
Immune Dysregulation
Hepatic Encephalopathy
Acute Liver Injury
Acute Liver Failure

Interventions: Drug: High-dose methylprednisolone
Drug: Equine anti-thymocyte globulin
Drug: Placebo for prednisolone
Drug: Placebo for infusions
Drug: Prednisolone
Drug: Diphenhydramine
Drug: Methylprednisolone

First Posted Date: 2021-04-27

Last Posted Date: 2024-07-01

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Target Recruit Count: 163

Registration Number: NCT04862221

Locations: 🇺🇸
Emory Children's Healthcare of Atlanta, Atlanta, Georgia, United States
🇺🇸
Cleveland Clinic Children's, Cleveland, Ohio, United States
🇺🇸
The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States

and more 19 locations

Intratumor Injection of Anti-Mesothelin Immunotoxin LMB-100 With Ipilimumab in Malignant Mesothelioma

Phase 1

Terminated

Conditions: Mesothelioma

Interventions: Biological: LMB-100
Drug: ipilimumab
Drug: Diphenhydramine
Drug: Famotidine
Drug: Acetaminophen
Drug: Dexamethasone
Procedure: Biopsy
Diagnostic Test: FDG-PET
Diagnostic Test: CT CAP
Diagnostic Test: MRI
Diagnostic Test: ECG
Diagnostic Test: Echocardiogram

First Posted Date: 2021-04-12

Last Posted Date: 2024-02-02

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 2

Registration Number: NCT04840615

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Evaluation of Peripheral Itch Mechanisms Following Injection of Morphine (Second Sub-Project)

Not Applicable

Completed

Conditions: Itch

Interventions: Drug: Capsaicin
Drug: Diphenhydramine
Drug: Morphine Chloride
Drug: Isotonic saline
Drug: Histamine

First Posted Date: 2021-01-07

Last Posted Date: 2022-01-27

Lead Sponsor: Aalborg University

Target Recruit Count: 26

Registration Number: NCT04700007

Locations: 🇩🇰
Mech-Sense, Medicinsk Gastroenterologisk ambulatorium, Medicineshus, Aalborn Universitethospitalet, AAlborg, Nordjylland, Denmark

Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies

Phase 1

Active, not recruiting

Conditions: Recurrent Acute Leukemia
Recurrent B Acute Lymphoblastic Leukemia
Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm
Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Refractory Hairy Cell Leukemia
Refractory Hematologic Malignancy
Refractory Hodgkin Lymphoma
Refractory T Acute Lymphoblastic Leukemia
Systemic Mastocytosis

Interventions: Drug: Acetaminophen
Drug: Dexamethasone
Drug: Diphenhydramine
Biological: Flotetuzumab
Drug: Ibuprofen
Drug: Ranitidine

First Posted Date: 2020-12-23

Last Posted Date: 2023-12-20

Lead Sponsor: City of Hope Medical Center

Target Recruit Count: 13

Registration Number: NCT04681105

Locations: 🇺🇸
City of Hope Medical Center, Duarte, California, United States

A Study Evaluating the Efficacy and Safety of Obinutuzumab in Participants With Primary Membranous Nephropathy

Phase 3

Active, not recruiting

Conditions: Primary Membranous Nephropathy

Interventions: Drug: Obinutuzumab
Drug: Tacrolimus
Drug: Methylprednisolone
Drug: Acetaminophen
Drug: Diphenhydramine

First Posted Date: 2020-11-16

Last Posted Date: 2024-08-22

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 140

Registration Number: NCT04629248

Locations: 🇺🇦
Regional Clinical Hospital n.a I.I. Mechnicov, Dnipropetrovsk, Ukraine
🇺🇦
Ternopil University Hospital, Ternopil, Kherson Governorate, Ukraine
🇺🇸
Nephrotex Research Group, Dallas, Texas, United States

and more 52 locations

A Dose Escalation and Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7283420.

Phase 1

Completed

Conditions: Acute Myeloid Leukemia

Interventions: Drug: RO7283420
Drug: Tocilizumab
Drug: Dasatinib
Drug: Dexamethasone
Drug: Paracetamol/acetaminophen
Drug: Diphenhydramine

First Posted Date: 2020-10-08

Last Posted Date: 2024-06-03

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 59

Registration Number: NCT04580121

Locations: 🇮🇹
Ospedale Santa Chiara; Unita Operativa Di Ematologia, Pisa, Toscana, Italy
🇺🇸
UC Davis Comprehensive Cancer Center, Sacramento, California, United States
🇩🇰
Rigshospitalet; Hæmatologisk Klinik, Klinisk Afprøvnings Team KAT, København Ø, Denmark

and more 20 locations

Intermediate-size Expanded Access Program (EAP), Mesenchymal Stromal Cells (MSC) for Multisystem Inflammatory Syndrome in Children (MIS-C) Associated With Coronavirus Disease (COVID-19)

Conditions: Multisystem Inflammatory Syndrome in Children (MIS-C) Associated With Coronavirus Disease (COVID-19)

First Posted Date: 2020-07-02

Last Posted Date: 2023-05-06

Lead Sponsor: Mesoblast International Sàrl

Registration Number: NCT04456439

A Phase II Trial of Neoadjuvant Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) With Chemoradiation

Phase 2

Recruiting

Conditions: Gastric Cancer
Stomach Cancer

Interventions: Drug: Paclitaxel
Drug: Carboplatin
Drug: Dexamethasone
Drug: Diphenhydramine
Drug: Famotidine
Drug: Palonosetron
Radiation: 3D conformal or intensity modulated radiotherapy
Procedure: Surgical resection
Radiation: Adjuvant Chemotherapy

First Posted Date: 2020-03-16

Last Posted Date: 2023-11-14

Lead Sponsor: Icahn School of Medicine at Mount Sinai

Target Recruit Count: 29

Registration Number: NCT04308837

Locations: 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States
🇺🇸
Mount Sinai St. Luke's, New York, New York, United States
🇺🇸
Mount Sinai West, New York, New York, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy